Document:

Document

Exhibit 4.4
DESCRIPTION OF CAPITAL STOCK
General
The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Capital Stock,” you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, which are included as exhibits to our Annual Report on Form 10-K, and to the applicable provisions of Delaware law. Our authorized capital stock consists of 100,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share. Our board of directors is authorized, without stockholder approval except as required by the listing standards of the New York Stock Exchange to issue additional shares of our capital stock.
Common Stock
Voting Rights
Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. Our amended and restated certificate of incorporation does not provide for cumulative voting for the election of directors.
Economic Rights
Dividends and Distributions. Subject to the prior rights of holders of all classes and series of stock at the time outstanding having prior rights as to dividends, the holders of common stock are entitled to receive, when, as and if declared by the board of directors, out of any assets legally available therefor, such dividends as may be declared from time to time by the board of directors.
Liquidation Rights. In the event of our liquidation, dissolution, or winding-up, upon the completion of the distributions required with respect to any series of preferred stock that may then be outstanding, the remaining assets legally available for distribution to stockholders shall be distributed ratably among the holders of common stock.
Preferred Stock
Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges, and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing a change of control or other corporate action. No shares of preferred stock are currently outstanding, and we have no present plan to issue any shares of preferred stock.
Anti-Takeover Provisions
Delaware Law
We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:
•before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

•upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
•on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
In general, Section 203 defines business combination to include the following:
•any merger or consolidation involving the corporation and the interested stockholder;
•any sale, transfer, pledge, or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;
•subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
•any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
•the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges, or other financial benefits by or through the corporation.
In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaw Provisions
Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common stock outstanding are able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent. A special meeting of stockholders may be called by the majority of our whole board of directors, chair of the board of directors, or our chief executive officer.
In accordance with our amended and restated certificate of incorporation, our board of directors is currently divided into three classes with staggered terms. Commencing with the election of directors at the 2023 annual meeting of stockholders, all of our directors will stand for one-year terms and our board of directors will no longer be classified.
In addition, our amended and restated certificate of incorporation and amended and restated bylaws provide that the number of directors constituting our board of directors may be set only by a resolution adopted by a majority vote of our entire board of directors. Prior to the election of directors at the 2023 annual meeting of stockholders, our directors may be removed only for cause. Commencing with the election of directors at the 2023 annual meeting of stockholders, our directors may be removed either with or without cause. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that vacancies occurring on our board of directors and newly created directorships resulting from an increase in the authorized number of directors may be filled only by vote of a majority of the remaining members of our board of directors, even though less than a quorum. Our amended and restated certificate of incorporation and amended and restated bylaws provide that our board of directors is expressly authorized to adopt, amend, or repeal our bylaws, and require a supermajority stockholder vote to amend our bylaws and certain provisions of our certificate of incorporation.
Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect 

that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.
The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.
These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.
Choice of Forum
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.
Limitations of Liability and Indemnification
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and executive officers, and may indemnify our other officers, employees and other agents, to the fullest extent permitted by the Delaware General Corporation Law. However, Delaware law prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:
•any breach of the director’s duty of loyalty to us or to our stockholders;
•acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
•unlawful payment of dividends or unlawful stock repurchases or redemptions; and
•any transaction from which the director derived an improper personal benefit.
If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director’s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of nonmonetary relief, remain available under Delaware law. This provision also does not affect a director’s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we are also empowered to enter into indemnification agreements with our directors, officers, employees, and other agents and to purchase insurance on behalf of any person whom we are required or permitted to indemnify.
In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we have entered into indemnification agreements with each of our current directors, officers, and some employees. These agreements provide for the indemnification of such persons for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were serving in such capacity. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors, officers, and employees. Furthermore, we have obtained director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us.

The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder’s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.Exhibit 4.1

     

    FIFTH SUPPLEMENTAL INDENTURE

     

    This Fifth Supplemental Indenture, made as of May 13, 2022 (the “Supplemental Indenture”), to that certain Indenture dated as of July 15, 2019
      (as such indenture has been supplemented and amended by the First Supplemental Indenture, dated as of November 3, 2020, by the Second Supplemental Indenture, dated as of November 19, 2020, by the Third Supplemental Indenture, dated as of August 6,
      2021, and by the Fourth Supplemental Indenture, dated as of October 6, 2021, the “Existing Indenture” and the Existing Indenture, as it may from time to time be supplemented or amended by one or more additional indentures supplemental thereto
      entered into pursuant to the applicable provisions thereof, being hereinafter called the “Indenture”) among Aquestive Therapeutics, Inc., a Delaware corporation with an address at 30 Technology Drive, Warren, New Jersey 07059 (the “Issuer”),
      any Guarantor that becomes party thereto pursuant to Section 4.10 of the Existing Indenture, and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”) and as
      collateral agent (the “Collateral Agent”).

     

    WHEREAS, the Issuer has heretofore executed and delivered to the Trustee the Existing Indenture, providing for the issuance of an aggregate principal
      amount of up to $104.0 million of 12.5% Senior Secured Notes due 2025;

     

    WHEREAS, the Issuer proposes to amend the Existing Indenture (the “Proposed Amendments”), which amendments, pursuant to Section 9.02 of the
      Indenture, must be approved by the written consent of Holders of a majority in principal amount of the outstanding Notes voting as a single class (collectively, the “Required Holders”);

     

    WHEREAS, the Issuer has received and delivered to the Trustee and to the Collateral Agent the consent of the Required Holders to the Proposed
      Amendments (the “Holder Consent”);

     

    WHEREAS, the Issuer has been authorized by a resolution of its board of directors to enter into this Supplemental Indenture;

     

    WHEREAS, all other acts and proceedings required by law, by the Existing Indenture and by the certificate of incorporation and bylaws of the Issuer to
      make this Supplemental Indenture a valid and binding agreement for the purposes expressed herein, in accordance with its terms, have been duly done and performed;

     

    WHEREAS, pursuant to Section 9.02, the Trustee and the Collateral Agent are authorized to execute and deliver this Supplemental Indenture; and

     

    WHEREAS, following the execution of this Supplemental Indenture, the terms hereof will become operative on the date hereof.

     

    NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH:

     

    That, for and in consideration of the premises herein contained and in order to effect the Proposed Amendments contained herein, pursuant to Section
      9.02 of the Existing Indenture, the Issuer agrees with the Trustee and the Collateral Agent as follows:

     

    
      
        

    

    
    ARTICLE 1

     

    Amendment of Existing Indenture

     

    Section 1.01.        Amendment of Existing Indenture.  This Supplemental Indenture amends the Existing Indenture as
        provided for herein.

     

    Section 1.02.        Amendment of Section 1.01.  Pursuant to Section 9.02 of the Existing Indenture:

     

    (a)          the definition of the “First Additional Securities Triggering Event” in Section 1.01 of the
        Existing Indenture is hereby amended and restated in its entirety as follows:

     

    “First Additional Securities Triggering Event” means the full approval of Libervant by the FDA for sale in the United States, which full approval
      shall include market access.

     

    (b)          Section 1.01 of the Existing Indenture is hereby amended by inserting the following defined
        term in appropriate alphabetical order:

     

    “October 2020 Purchase Agreements” means those certain purchase agreements between the Company and the purchasers listed on Schedule 1 thereto, dated
      as of November 3, 2020.

     

    Section 1.03.       Amendment of Section 2.01.  Pursuant to Section 9.02 of the Existing Indenture, Sections 2.01(c)
        and (d) of the Existing Indenture are hereby amended by deleting all references therein to “June 30, 2022” and replacing them with “March 31, 2023”.

     

    Section 1.04.       Amendment of Section 4.19.  Pursuant to Section 9.02 of the Existing Indenture, Section 4.19 of
        the Existing Indenture are hereby amended:

     

    (a)         by deleting the text “the right to purchase an aggregate amount” and replacing it with the text
        “the right, but not the obligation, to purchase an aggregate amount”;

     

    (b)          by deleting the text “the right to purchase such remaining First Additional Securities or
        Second Additional Securities, as applicable” and replacing it with the text “the right, but not the obligation, to purchase such remaining First Additional Securities or Second Additional Securities, as applicable”;

     

    (c)          by deleting all references therein to “First Additional Notes” and replacing them with “First
        Additional Securities”;

     

    (d)          by deleting all references therein to “Second Additional Notes” and replacing them with
        “Second Additional Securities”; and

     

    (e)          by deleting the text “elect to exercise the Right of First Offer described above and” from the
        third paragraph thereof.

     

    
      2

      
        

    

    ARTICLE 2

     

       

    Miscellaneous Provisions

     

    Section 2.01.       Ratification of Indenture; Supplemental Indentures Part of Indenture.  Except as expressly amended
        and supplemented hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture for all
        purposes, and every Holder shall be bound hereby.

     

    Section 2.02.       Defined Terms.  As used in this Supplemental Indenture, terms defined in the Indenture or in the
        preamble or recitals hereto are used herein as therein defined, except that the term “Holders” in this Supplemental Indenture shall refer to the term “Holders” as defined in the Indenture and the Trustee and the Collateral Agent acting on behalf of
        and for the benefit of such Holders.  The words “herein”, “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

     

    Section 2.03.       Counterparts.  The parties may sign any number of copies of this Supplemental Indenture.  Each
        signed copy shall be an original, but all of them together represent the same agreement.  The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and
        delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original
        signatures for all purposes.

     

    Section 2.04.        Effect of Headings.  The Section headings herein are for convenience of reference only and shall
        not affect the construction thereof.

     

    Section 2.05.        Effectiveness.  The provisions of this Supplemental Indenture will take effect immediately upon
        execution thereof by the parties hereto.

     

    Section 2.06.      Governing Law.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH
        THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

     

    Section 2.07.      No Representation; Recitals.  Neither the Trustee nor the Collateral Agent makes any representation
        as to the validity or sufficiency of this Supplemental Indenture. The recitals to this Supplemental Indenture are made solely by the Issuer and shall not be attributable to the Trustee or the Collateral Agent.

     

    {Remainder of page intentionally left blank}

     

    
      3

      
        

    

    IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of the date first written above.

     

    	 	
            AQUESTIVE THERAPEUTICS, INC.

          
	 	 
	 	
            By:

          	
            /s/ Keith Kendall

          
	 	 	 
	 	 	
            Name: Keith Kendall

          
	 	 	
            Title: President & CEO

          

    

       

    Signature Page to the Fifth Supplemental Indenture

    

       

    
      
        

    

    	 	
            U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION,

          
	 	
            as Trustee

          
	 	 
	 	
            By:

          	
            /s/ Alison D.B. Nadeau

          
	 	 	
            Name: Alison D.B. Nadeau

          
	 	 	
            Title: Vice President

          
	 	 	 
	 	
            U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION,

          
	 	
            as Collateral Agent

          
	 	 
	 	
            By:

          	
            /s/ Alison D.B. Nadeau

          	 
	 	 	
            Name: Alison D.B. Nadeau

          
	 	 	
            Title: Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]